Syndax Pharmaceuticals (NASDAQ:SNDX) Raised to “Sell” at StockNews.com
Syndax Pharmaceuticals (NASDAQ:SNDX – Get Free Report) was upgraded by investment analysts at StockNews.com to a “sell” rating in a report released on Tuesday. SNDX has been the topic of a number of other reports. Citigroup cut their price objective on Syndax Pharmaceuticals from $45.00 to $42.00 and set a “buy” rating on the stock […]
Syndax Pharmaceuticals (NASDAQ:SNDX – Get Free Report) was upgraded by investment analysts at StockNews.com to a “sell” rating in a report released on Tuesday. SNDX has been the topic of a number of other reports. Citigroup cut their price objective on Syndax Pharmaceuticals from $45.00 to $42.00 and set a “buy” rating on the stock […]
